CClinicalTrials.gg
CompletedNCT03339466Updated Jan 29, 2024

Inspiratory Muscle Therapy in Subjects With Fontan Circulations

An interventional study of Inspiratory muscle therapy in Single-ventricle, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-29.

Sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Individuals who have undergone the Fontan procedure are uniquely dependent upon respiratory mechanics to support pulmonary blood flow (PBF). The investigators hypothesized that enhanced respiratory muscle function via inspiratory muscle training (IMT) would improve performance on cardiopulmonary exercise stress testing (CPET).

Read the detailed description

Adult Fontan subjects were recruited from 2 academic medical centers. Following characterization of pulmonary function and functional class, CPET was performed using incremental and constant work rate protocols. Subjects performed 6-8 weeks of IMT using a handheld inspiratory loading device (Threshold®, Philips); both exercise tests were then repeated. Patient-centered outcome data were collected before and after IMT (RAND-36 assessment and New York Heart Association (NYHA) functional class).

02

Conditions studied

03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Single ventricle physiology status post Fontan palliation

Exclusion criteria

Exclusion Criteria:

  • The presence of a sub-pulmonary ventricle
  • Pregnancy or any contraindication to stress testing (e.g., uncontrolled symptomatic arrhythmia, severe systemic ventricular outflow tract obstruction or uncontrolled symptomatic heart failure).
  • Height less than 4'11" due to limitations of the cycle ergometer.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Experimental arm - Inspiratory Muscle Training

    Single arm study. All subjects will perform 6-8 weeks of inspiratory muscle therapy with cardiopulmonary stress test (both standard and constant work rate) before and after intervention.

    Device: Inspiratory muscle therapy

Interventions

  • DeviceInspiratory muscle therapy

    6 weeks of inspiratory muscle therapy

    Also known as: No other interventions. Subjects will serve as their own control; single arm study.

05

What researchers measure

Primary outcomes

  1. Exercise parameters

    Peak VO2 and endurance time are the primary outcome measures

    Time frame: 6-8 weeks

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03339466
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Responsible party
Priya Pillutla (Physician Specialist, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center) — Principal investigator
First posted
Nov 13, 2017
Start date
Jan 29, 2016
Primary completion
Aug 24, 2016
Completion
Aug 31, 2017
Last update
Jan 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion